Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Finance

17 May 2022

Microdose’s Deal Board Helps Democratize Psychedelic Investing

Microdose is doing its part in helping democratize investment opportunities....

By Microdose

Events

16 May 2022

Plant Medicine Week 2022: European Psychedelic Clinics and Retreats

This Plant Medicine Week panel was joined by a solid group of experts discussing the model and industry of psychedelic therapy clinics and retreats....

By Microdose

Press Releases

16 May 2022

Dr. Dennis McKenna to Host Historic Livestream Psychoactive Symposium

The McKenna Academy of Natural Philosophy hosts its first Ethnopharmacologic Search for Psychoactive Drugs (ESPD55) event on May 23-26th, 2022....

By Microdose

Events

13 May 2022

Plant Medicine Week 2022: Psychedelic Capital Panel

Day one of the psychedelic portion of Plant Medicine Week saw a solid lineup of panels....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Events

9 May 2022

Plant Medicine Week 2022: Meet The Sponsors

Putting on Plant Medicine Week wouldn’t be possible without the support of our sponsors, they are crucial to both the event and the future of the psychedelic medicine industry....

By Microdose

Events

7 May 2022

Plant Medicine Week 2022: Microdosing Clinical Trials

Justin Hanka from MindBio Therapeutics was one of the keynote speakers at Plant Medicine Week, and his company is positioning itself as a leader in this LSD renaissance....

By Microdose

Events

5 May 2022

Plant Medicine Week 2022: Psychedelics and Women’s Health

Can psychedelic medicine address women’s issues? Can they help with mental and physical challenges related to PMS, menopause, and Hypoactive Sexual Desire Disorder (HSDD)?...

By Microdose

Law & Politics

3 May 2022

Non-Profit TheraPsil Raising Funds to Fight for Psilocybin Access

May is Mental Health Awareness Month in the US (this week is Mental Health Week in Canada)....

By Microdose

Events

2 May 2022

Plant Medicine Week 2022: The Development of Psychedelics Outside of Mood Disorders

As the final day of Plant Medicine Week began to wind down, attendees were treated to an informative panel on the evolution and expansion of the industry....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.